Veracyte Reported that Publication of Data Supporting Clinical Utility of the Percepta® Bronchial Genomic Classifier in Lung Cancer Diagnosis

Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced that data supporting the ability of the company’s Percepta Bronchial Genomic Classifier to help reduce unnecessary, invasive procedures in lung cancer diagnosis were published online in CHEST, the official journal of the American College of Chest Physicians.
According to the company news:

Utilizing data from two prospective, multicenter studies,^1,2 researchers determined that use of the Percepta classifier could have decreased unnecessary, invasive procedures in 50 percent of the evaluated patient population. The study analyzed patients with lung nodules or lesions whose bronchoscopy results were inconclusive for cancer and who were considered to have an intermediate or low risk of cancer prior to use of the Percepta classifier. The genomic test has previously been shown to have high accuracy when it identified lung nodules or lesions as low risk for cancer among this population.

Anil Vachani, M.D., University of Pennsylvania School of Medicine and lead author of the CHEST paper said

As the number of lung nodules and lesions are increasing due to both incidental findings and expanding lung cancer screening programs, providers need clinically proven tools to help them more confidently determine which patients can be followed with CT scans and avoid additional, invasive and potentially risky tests. Our findings suggest that use of the Percepta classifier may help reduce the frequency and associated morbidity of invasive procedures in lung cancer diagnosis.

Click here to view the full press release.